BACKGROUND - The aim of the study was to investigate whether RCC patients with oligometastatic state of bone metastasis treated with sunitinib had a favorable clinical outcome.
RESULTS - 22 patients were classified into oligometastatic state of bone metastasis with a median OS of 30.
1 months (95%CI: 26.3 to 33.8 months). The 45 patients with non-oligometastatic state had a median OS of 12.7 months (95%CI: 9.43 to 16.0 months). Kaplan-Meier analysis showed significant difference between them (Log Rank test p<0.001). When we set patients with only multiple bone (at least 5 sites) metastases as a single group, there was still significant difference between oligometastatic state group and non-oligometastatic state groups. In multivariate Cox proportion hazard ratio analysis, metastatic states (p=0.012), MSKCC score (p=0.002), ECOG (p=0.001) and lymph nodes metastasis (p=0.000) were significantly associated with prognosis. The integration of metastatic state into the MSKCC risk model improved the c-index from 0.651 to 0.752 Method: 67 patients from Fudan University Shanghai Cancer Center with bone metastatic RCC were divided into 2 metastatic states. One included those with oligometastatic state of bone metastasis with less than 5 sites of bone metastasis. The other involved those patients with multiple bone metastases (at least 5 sites) or together with other sites of metastasis. Then patients with only multiple bone (at least 5 sites) metastases were set into a single group.
CONCLUSIONS - RCC patients with oligometastatic state of bone metastasis treated with sunitinib had a favorable clinical outcome.
Oncotarget. 2016 Apr 04 [Epub ahead of print]
Xiaolin Lu, Weijie Gu, Hailiang Zhang, Yao Zhu, Guohai Shi, Dingwei Ye
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China., Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China., Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China., Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China., Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China., Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.